newwin
Luciann Nguyen
Settings
← Accounts
biotech

Tango Therapeutics, Inc.

53
Account opportunity
Not established
Relationship
1
Active signals
1
Trials as sponsor

Why this account matters

Tango Therapeutics, Inc.

New trial — Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

New trialNCT05887492
53/100
Opportunity
Commercial fit11/25
Clinical timing20/20
Biomarker need5/20
Relationship2/10
Signal strength9/10
Account value5/10
Urgency1/5

New phase 1_2 trial NCT05887492 posted by Tango Therapeutics, Inc.: "Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors". New trial on a phase 1_2 active not recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 64 days ago.

ConfidenceHigh · 87%clinical development · translational medicine · clinical operations
Draft outreachReview

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

TrialPhaseTesting language
NCT05887492
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
phase 1 2
mol. elig.